tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Regeneron price target raised to $875 from $750 at Evercore ISI
PremiumThe FlyRegeneron price target raised to $875 from $750 at Evercore ISI
7d ago
Regeneron Explores New Intralesional Use for Libtayo in Skin Cancer: What Investors Should Know
Premium
Company Announcements
Regeneron Explores New Intralesional Use for Libtayo in Skin Cancer: What Investors Should Know
7d ago
Regeneron Pharmaceuticals: Dupixent-Driven Growth Offset by Patent Uncertainty, Supporting a Hold Rating
Premium
Ratings
Regeneron Pharmaceuticals: Dupixent-Driven Growth Offset by Patent Uncertainty, Supporting a Hold Rating
8d ago
Regeneron price target raised to $914 from $807 at Goldman Sachs
PremiumThe FlyRegeneron price target raised to $914 from $807 at Goldman Sachs
21d ago
Anavex appoints Wolfgang Liedtke as SVP, global head of neurologyRegeneron
Premium
The Fly
Anavex appoints Wolfgang Liedtke as SVP, global head of neurologyRegeneron
21d ago
Midday Fly By: Warner Bros. urges holders to reject Paramount bid
Premium
The Fly
Midday Fly By: Warner Bros. urges holders to reject Paramount bid
21d ago
Regeneron upgraded to Buy from Underperform at BofA
PremiumThe FlyRegeneron upgraded to Buy from Underperform at BofA
22d ago
Sanofi and Regeneron Expand Dupilumab’s Real-World Footprint in Chronic Urticaria
Premium
Company Announcements
Sanofi and Regeneron Expand Dupilumab’s Real-World Footprint in Chronic Urticaria
23d ago
Regeneron Advances Phase 3 Antibody Trial in Birch Pollen Eye Allergy: What Investors Should Know
Premium
Company Announcements
Regeneron Advances Phase 3 Antibody Trial in Birch Pollen Eye Allergy: What Investors Should Know
29d ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100